ArticleESC heart failure2025
Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012-2022.
Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Remote Management of Patients With Heart Failure in Medically Underserved Areas.JACC. Advances · 2026Article
- Follow-Up of Left-Ventricular Assist Device Patients With Telemonitoring: A National Retrospective Multicentric Study on the Satelia LVAD Web Application.Artificial organs · 2026Article
- Hospitalisation for acute heart failure and in-hospital mortality before, during and after the COVID-19 pandemic in France: a nationwide cohort study from 2013 to 2024.BMJ public health · 2026Article
- Sex-based differences in heart failure management and outcomes: Insights from the French-DataHF cohort.European journal of heart failure · 2025Article
- Updated Trends in Valvular Heart Disease-Related Heart Failure in G20-the Group of Twenty Countries: Insights From the Global Burden of Disease Study 2021.Reviews in cardiovascular medicine · 2025Article
- Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012-2022.ESC heart failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsWe aim to describe the incidence of HF hospitalization in France in the post-pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio-economic differences and to analyse time-trends between 2012 and 2022. METHODS AND
resultsBased on the French health care database providing medical information for almost the whole French population, patients hospitalized for acute decompensated HF without history of HF in the 5 years were identified by the International Classification of Diseases - 10th revision (ICD-10) codes. In 2022, the estimated prevalence of HF was 1.7% in France and has increased until the COVID-19 pandemic and decreased thereafter. The incidence of acute HF decompensation reached 201.4 per 100 000 inhabitants and has decreased since 2012 (-1% per year). A significant increase of the HF incidence was found in men aged <45 years. Women aged <65 years were less likely to be admitted in a cardiac rehabilitation (CR) unit and had higher probability of one-year mortality compared with men of the same age. One-year mortality was significantly increased in patients from the most deprived area among extreme age group only (under 65 and ≥85 years). One-year rehospitalization rates have decreased significantly, particularly in men aged <75 years. A decrease in ACE/ARBs deliveries was observed in both men and women.
conclusionsDespite the decrease in acute HF decompensation incidence and improvements in the management, the prevalence of HF remains stable in France and prognosis remains poor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.